Tag: personalized medicine

————-

The following is Part 2 of a two-part series (see part one here) exploring how pharmacogenetic (PGx) testing can help senior living communities navigate medication conversations and support more personalized care. The series is written by Dr. Troy Veale, CEO of PHD Laboratory, a healthcare innovator with more than 25 years of experience in behavioral health and over a decade in laboratory science focused on advancing precision medicine and improving patient outcomes.

————-

In Part 1, we explored why medication conversations matter in senior living environments. In Part 2, we turn to the clinical side of pharmacogenetic (PGx) testing, what it is, what it is not, and why it holds particular relevance for aging populations.

WHAT PGx TESTING ACTUALLY EVALUATES

Pharmacogenetic testing analyzes specific genes that influence how medications are metabolized. Using a non-invasive cheek swab, laboratories evaluate genetic markers related to drug-processing enzymes, particularly those that impact common prescriptions used in aging adults.

Results may indicate whether an individual is likely to:

• Metabolize a medication too quickly (reducing effectiveness)
• Metabolize it too slowly (increasing side effect risk)
• Process it as expected
• Benefit from alternative medication classes

The goal is not to dictate therapy but to provide additional data to support provider judgment.

WHY AGING POPULATIONS BENEFIT FROM PERSONALIZATION

Older adults are more susceptible to adverse drug reactions for several reasons:

• Decreased liver and kidney function
• Changes in body composition
• Multiple coexisting health conditions
• Polypharmacy (use of multiple medications)

Research consistently shows that adverse drug events are a leading cause of emergency department visits among older adults. Even when medications are appropriately prescribed, genetic variation can influence response.

PGx testing brings that variability into clearer focus.

ADDRESSING COMMON MYTHS

Myth 1: PGx testing is only for complex cases.
In reality, many commonly prescribed medications,  including those for cardiovascular health, depression, pain, and neurology — have pharmacogenetic considerations.

Myth 2: Stable patients don’t need this information.
Even stable residents may benefit from minimizing long-term risk or identifying lower-risk alternatives.

Myth 3: It replaces physician expertise.
PGx testing enhances decision-making. Providers interpret results within the context of medical history and clinical presentation.

Myth 4: It is invasive or risky.
The test requires only a simple cheek swab.

BENEFITS ACROSS STAKEHOLDERS

For providers:

• Additional prescribing insight
• Support for medication adjustments
• Alignment with evidence-informed care

For senior living teams:

• Stronger educational positioning
• Confidence in discussing holistic care
• Alignment with preventative models

For families:

• Greater transparency
• Reduced uncertainty
• Peace of mind

Medication conversations become proactive rather than reactive.

PRIVACY, COVERAGE AND NEXT STEPS

Your DNA is used only to analyze how your body processes medications. PHD Laboratory does not sell, share, or store your DNA for any other purpose. We are CLIA and COLA certified and fully compliant with HIPAA privacy laws, ensuring your genetic information is protected and confidential at all times.

PGx testing is covered by Medicare Part B for eligible patients and may also be paid for using FSA/HSA funds, CareCredit, or private pay options.

For questions, educational information, or to order a PGx test, please visit the PHD Laboratory website or email info@phdlaboratory.com.

————-

The following is Part 1 of a two-part series exploring how pharmacogenetic (PGx) testing can help senior living communities navigate medication conversations and support more personalized care. The series is written by Dr. Troy Veale, CEO of PHD Laboratory, a healthcare innovator with more than 25 years of experience in behavioral health and over a decade in laboratory science focused on advancing precision medicine and improving patient outcomes.

————-
In senior living, some of the most important conversations don’t happen on a tour, they happen around medications.

Families ask questions quietly:

• Why is Mom more tired lately?
• Is this medication causing confusion?
• Why does this prescription work for one resident but not another?

Medication management is often treated as a clinical back-office issue. But in reality, it directly affects resident satisfaction, outcomes, staff confidence, and family trust.

For senior living sales teams, executive directors, nurses, and caregivers, medication conversations present both a challenge and an opportunity. The challenge is complexity. The opportunity is education.

One emerging tool helping shift these discussions is pharmacogenetic (PGx) testing, not as a sales pitch, and not as a replacement for physician oversight, but as a framework for clearer conversations.

Why Medication Conversations Feel Overwhelming

Older adults frequently manage multiple chronic conditions, cardiovascular disease, diabetes, depression, chronic pain, neurological disorders. It is not uncommon for residents to take five, ten, or even more medications daily.

With aging comes physiological changes that affect how the body absorbs, metabolizes, and eliminates drugs. These changes can increase the risk of:

• Adverse drug reactions
• Falls and dizziness
• Increased confusion
• Medication non-adherence due to side effects
• Avoidable hospitalizations

Families often assume these risks are simply “part of aging.” Teams sometimes assume side effects are unavoidable. Providers do their best with the information available.

But what if medication conversations didn’t have to start from a place of guesswork?

A Shift Toward Personalization

PGx testing evaluates how a person’s genetics may influence the way certain medications are processed in the body. It doesn’t diagnose disease. It doesn’t predict future illness. It provides insight into how medications may interact with an individual’s metabolic profile.

For senior living professionals, the most powerful part of PGx testing isn’t the lab result, it’s the conversation it opens.

It creates space to ask:

• Is this medication optimal for this individual?
• Could side effects be reduced?
• Are there alternatives that may align better?
• How can we support safer prescribing conversations?

These are not clinical determinations made by sales staff or caregivers. They are informed discussions that support provider evaluation and collaborative care planning. 

Trust Is Built Through Transparency

Senior living is built on trust. Families are not just choosing a community; they are choosing partners in care.

When medication conversations are proactive rather than reactive, families feel:

• Heard
• Educated
• Involved
• Reassured

Communities that introduce the idea of personalized medication discussions demonstrate alignment with preventative and value-based care models.

Sales teams are uniquely positioned here. They can frame PGx testing as a supportive educational resource, one that enhances provider decision-making and resident well-being.

Rather than saying, “We offer genetic testing,” the conversation becomes:

“We believe in helping families feel confident in every aspect of care — including medications.”

Removing Barriers, Not Adding Complexity

One concern often raised is whether introducing PGx testing adds another layer of complexity to an already overwhelming process. The opposite can be true.

By helping providers evaluate medication suitability earlier rather than later, PGx testing may reduce future medication adjustments, side effects, or avoidable emergency visits. It simplifies long-term decision-making by introducing clearer data into the process.

For caregivers and daughters like Michele, who recently navigated placing her own mother into senior living, clarity around medications is deeply personal. Families want assurance that their loved one is not simply “trying medications”, but receiving informed, thoughtful care.

PGx testing supports that reassurance.

A New Category of Conversation

Senior living has evolved to include partnerships in move management, downsizing, care coordination, and wellness programming. Medication personalization is a natural extension of holistic senior care.

This isn’t about replacing physicians. It isn’t about overstepping clinical boundaries. It’s about strengthening education, transparency, and collaboration.

In Part 2, we will explore the clinical foundation behind PGx testing, how it works, common myths, and why it continues gaining traction in aging populations.

Privacy, Coverage, and Next Steps

Your DNA is used only to analyze how your body processes medications. PHD Laboratory does not sell, share, or store your DNA for any other purpose. We are CLIA and COLA certified and fully compliant with HIPAA privacy laws, ensuring your genetic information is protected and confidential at all times.

PGx testing is covered by Medicare Part B for eligible patients and may also be paid for using FSA/HSA funds, CareCredit, or private pay options.

For questions, educational information, or to order a PGx test, please visit the PHD Laboratory website or email info@phdlaboratory.com.